Here's How Merck Plans to Protect Billions of Dollars in Sales
Merck has intriguing new diabetes drugs in development that could blunt any market share risk following Eli Lilly's positive phase 3 trial results for Jardiance.
Will the FDA Approve All 3 of These Cancer Drugs in October?
Three cancer drugs are slated to go before the proverbial firing squad in October. Will the Food and Drug Administration green light all three?
Eli Lilly Officially Puts Merck on Notice
Eli Lilly and partner Boehringer Ingelheim release their highly-anticipated EMPA-REG OUTCOME data on Jardiance, and it doesn't disappoint.